1. Real-world evidence of NEPA, netupitant-palonosetron, in chemotherapy-induced nausea and vomiting prevention: effects on quality of life
- Author
-
Jörg Schilling, Pia Wülfing, Elisa Flahaut, Carsten Hielscher, Mark-Oliver Zahn, Dagmar Guth, Meinolf Karthaus, and Gülten Oskay-Özcelik
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Pyridines ,Vomiting ,medicine.drug_class ,Nausea ,Real world evidence ,03 medical and health sciences ,0302 clinical medicine ,Quality of life ,Neoplasms ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Antiemetic ,Prospective Studies ,030212 general & internal medicine ,Summary of Product Characteristics ,Aged ,Aged, 80 and over ,business.industry ,General Medicine ,Middle Aged ,Palonosetron ,Treatment Outcome ,Oncology ,030220 oncology & carcinogenesis ,Quality of Life ,Drug Therapy, Combination ,Female ,medicine.symptom ,business ,Highly emetogenic chemotherapy ,Chemotherapy-induced nausea and vomiting - Abstract
Aim: To determine quality of life, effectiveness and safety of oral netupitant-palonosetron (NEPA)–based antiemetic prophylaxis in the real-world setting. Materials & methods: Prospective, noninterventional study in adults receiving highly or moderately emetogenic chemotherapy and NEPA for three cycles. NEPA was administered per summary of product characteristics. Results: A total of 2429 patients enrolled, 2173 were evaluable. ‘No impact on daily life’ due to vomiting was reported by 84%/82% of patients in the highly emetogenic chemotherapy/moderately emetogenic chemotherapy groups in cycle 1, with rates of 54%/59% for nausea. Overall, complete response rate was 89%/87%/83% in the acute/delayed/overall phases. NEPA was well tolerated. Conclusion: NEPA had beneficial effects on the quality of life of a heterogeneous group of cancer patients and was safe and effective in the real-world setting.
- Published
- 2020